Cardiovascular Diseases
Conditions
Keywords
Adherence, Morisky Medication Adherence Scale, Beliefs about Medicines Questionnaire, Medication Possession Ratio, Medication-Related Problems, Pharmacist, Pharmacist Intervention, Pharmacy, Pharmacy Service, Pharmacy Practice, Hypertension, Antihypertensive Agents, Anticoagulants, Statins, Dyslipidemia
Brief summary
Medisinstart is a new service developed for use in Norwegian pharmacies. It is intended for patients that are about to start a new medicine for a chronic or long-term condition. It is based on research showing that problems with newly prescribed medicines appear rapidly and that a significant portion of patients quickly becomes non-adherent. The service consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine. The main purpose of this study is to investigate whether Medisinstart increases patients' adherence to the prescribed medication. Patients' beliefs about their medicines and their motivation for adherence will also be examined. The study also aims at revealing if Medisinstart has additional benefits for the patient, the society and the pharmacies.
Interventions
OTHERMedisinstart
Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.
Sponsors
Norwegian Pharmacy Association
Apokus AS
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
First time prescription for a drug belonging to one of the following groups (ATC-code): * Dabigatran etexilate (B01AE07) * Rivaroxaban (B01AF01) * Apixaban (B01AF02) * Beta blocking agents (C07) * Calcium channel blockers (C08) * Agents acting on the renin-angiotensin system (C09) * HMG CoA reductase inhibitors (statins) (C10AA)
Exclusion criteria
* Prior use (within the last 3 years) of the drug in question independent of strength, dose and formulation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adherence by Morisky 8-item Medication Adherence Scale (MMAS-8) at 7 weeks | 7 weeks after dispensing the new medicine | Adherence will be measured by a validated Norwegian translation of the MMAS-8 |
| Adherence by Morisky 8-item Medication Adherence Scale (MMAS-8) at 18 weeks | 18 weeks after dispensing the new medicine | Adherence will be measured by a validated Norwegian translation of the MMAS-8 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adherence by Medication Possession Ratio (MPR) at 18 weeks | 18 weeks after dispensing the new medicine | Adherence by MPR will be calculated from data collected from the Norwegian Prescription Database |
| Self reported adherence at 18 weeks | 18 weeks after dispensing the new medicine | Adherence will be measured by a Norwegian translation of the question: People often miss taking doses of their medicines, for a wide range of reasons. Have you missed any doses of your new medicine the last week? |
| Adherence by Medication Possession Ratio (MPR) at 1 year | 1 year after dispensing the new medicine | Adherence by MPR will be calculated from data collected from the Norwegian Prescription Database |
| Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at 7 weeks | 7 weeks after dispensing the new medicine | Patients' beliefs about their medicines will be measured by a validated Norwegian translation of the BMQ |
| Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at 18 weeks | 18 weeks after dispensing the new medicine | Patients' beliefs about their medicines will be measured by a validated Norwegian translation of the BMQ |
| Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at inclusion | At inclusion | Patients' beliefs about their medicines will be measured by a validated Norwegian translation of the BMQ |
| Self reported adherence at 7 weeks | 7 weeks after dispensing the new medicine | Adherence will be measured by a Norwegian translation of the question: People often miss taking doses of their medicines, for a wide range of reasons. Have you missed any doses of your new medicine the last week? |
Other
| Measure | Time frame | Description |
|---|---|---|
| Pharmacy costs by performing the service | 1 year after study start | Pharmacies will report the COSTs for carrying out the service |
| Pharmacists' evaluation of patient benefit | 7 months after start of the study | Pharmacists performing the service will answer the following question (translated from Norwegian): You have currently performed Medisinstart with at least 5 patients. Do you regard it to be beneficial for the patients? |
| Patients' evaluation of Medisinstart | 7 weeks after dispensing the new medicine | Patients' in the intervention arm will evaluate the service by answering a questionnaire |
| Number of reported Medication-Related Problems in the intervention arm | During the intervention | The pharmacist carrying out the intervention will report all discovered Medication-Related Problems |
Countries
Norway
Outcome results
None listed